γ-干擾素
IFN-γ | |||||||||
---|---|---|---|---|---|---|---|---|---|
鑑定 | |||||||||
標誌 | ? | ||||||||
Pfam | PF00714(舊版) | ||||||||
Pfam宗系 | CL0053(舊版) | ||||||||
InterPro | IPR002069 | ||||||||
SCOP | 1rfb / SUPFAM | ||||||||
|
臨床資料 | |
---|---|
商品名 | Actimmune |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601152 |
ATC碼 | |
識別資訊 | |
| |
CAS號 | 82115-62-6 98059-61-1 |
DrugBank | |
ChemSpider | |
ChEMBL | |
化學資訊 | |
化學式 | C761H1206N214O225S6 |
摩爾質量 | 17145.6 g/mol |
干擾素-γ(Interferon gamma、Interferon-γ、IFNG、IFNγ)是水溶性二聚體的細胞因子[2]。是II型干擾素的唯一成員[3]曾被稱為巨噬細胞活化因子。
結構
干擾素-γ的單體是由六個α螺旋組成一個核心[4]和在C端區延伸展開的片斷序列。
生物活性
所有的細胞都可以產生干擾素-α和干擾素-β, 而干擾素-γ只由自然殺傷細胞(NK細胞)和活化的T細胞產生。I型干擾素對酸穩定,而干擾素-γ則遇酸變性。
干擾素-γ具有抗病毒、免疫調節及抗腫瘤特性[5]。干擾素-γ可以與干擾素伽瑪受體(IFNGR)結合,進而調節JAK-STAT通路。干擾素-γ激活抗原提呈細胞,通過上調轉錄因子T-bet而促進I型輔助T細胞(Th1細胞)的分化。
干擾素-γ是I型輔助T細胞(Th1細胞)的標誌性的細胞因子。II型輔助T細胞(Th2細胞)釋放白血球介素-4(IL-4)和白血球介素-13(IL-13)。自然殺傷細胞和CD8+T細胞也產生干擾素-γ。干擾素-γ通過迅速降解RANK-RANKL信號通路的TRAF6而抑制破骨細胞形成。
治療用途
干擾素可以用來治療傳染病,但也能促成自體免疫。在接受干擾素伽瑪治療的病人中,多達19%的病人會有自體免疫.
干擾素IFNγ用於豬生殖與呼吸道綜合症PRRSV的治療上,有試驗發現干擾素IFNγ能活化先天免疫細胞,進而達到抑制病毒數量的效果。[6]
A型流感的治療上,也有小鼠試驗表現出當缺失干擾素後,流感感染小鼠死亡率大幅提升且體內病毒數量維持高濃度水平;相較之下,體內有干擾素存在的小鼠,流感病毒數量隨著干擾素的生成而逐漸下降。[7]
參考文獻
- ^ PDB 1FG9; Thiel DJ, le Du MH, Walter RL, D'Arcy A, Chène C, Fountoulakis M, Garotta G, Winkler FK, Ealick SE. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. Structure. September 2000, 8 (9): 927–36. PMID 10986460. doi:10.1016/S0969-2126(00)00184-2.
- ^ Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature. 1982 Aug 26;298(5877):859-63.
- ^ Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature. August 1982, 298 (5877): 859–63. PMID 6180322. doi:10.1038/298859a0.
- ^ Ealick SE, et al., Three-dimensional structure of recombinant human interferon-gamma. Science. 1991 May 3;252(5006):698-702.
- ^ Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004 Feb;75(2):163-89.
- ^ Bautista, E. M.; Molitor, T. W. IFNγ inhibits porcine reproductive and respiratory syndrome virus replication in macrophages. Archives of Virology. 1999-06, 144 (6): 1191–1200. ISSN 0304-8608. doi:10.1007/s007050050578.
- ^ Hoshino, Akinori; Takenaka, Hiroshi; Mizukoshi, Osamu; Imanishi, Jiro; Kishida, Tsunataro; Tovey, Michael G. Effect of anti-interferon serum of influenza virus infection in mice. Antiviral Research. 1983-03, 3 (1): 59–65. ISSN 0166-3542. doi:10.1016/0166-3542(83)90015-3.
延伸閱讀
- Hall, Stephen K. A commotion in the blood: life, death, and the immune system. New York: Henry Holt. 1997. ISBN 0-8050-5841-9.
- Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting.. Cytokine Growth Factor Rev. 2002, 13 (2): 95–109. PMID 11900986. doi:10.1016/S1359-6101(01)00038-7.
- Chesler DA, Reiss CS. The role of IFN-gamma in immune responses to viral infections of the central nervous system.. Cytokine Growth Factor Rev. 2003, 13 (6): 441–54. PMID 12401479. doi:10.1016/S1359-6101(02)00044-8.
- Dessein A, Kouriba B, Eboumbou C, Dessein H, Argiro L, Marquet S, Elwali NE, Rodrigues V, Li Y, Doumbo O, Chevillard C. Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis.. Immunol. Rev. 2005, 201: 180–90. PMID 15361241. doi:10.1111/j.0105-2896.2004.00195.x.
- Joseph AM, Kumar M, Mitra D. Nef: "necessary and enforcing factor" in HIV infection.. Curr. HIV Res. 2005, 3 (1): 87–94. PMID 15638726. doi:10.2174/1570162052773013.
- Copeland KF. Modulation of HIV-1 transcription by cytokines and chemokines.. Mini reviews in medicinal chemistry. 2006, 5 (12): 1093–101. PMID 16375755. doi:10.2174/138955705774933383.
- Chiba H, Kojima T, Osanai M, Sawada N. The significance of interferon-gamma-triggered internalization of tight-junction proteins in inflammatory bowel disease.. Sci. STKE. 2006, 2006 (316): pe1. PMID 16391178. doi:10.1126/stke.3162006pe1.
- Tellides G, Pober JS. Interferon-gamma axis in graft arteriosclerosis.. Circ. Res. 2007, 100 (5): 622–32. PMID 17363708. doi:10.1161/01.RES.0000258861.72279.29.